Clinical Trial Update: Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating a recombinant attenuated Salmonella Typhi vaccine vector expressing Streptococcus pneumoniae PspA; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia

Drugs mentioned

• Recombinant Attenuated Salmonella Typhi Vaccine Vector Producing Streptococcus pneumoniae PspA (Recombinant attenuated Salmonella Typhi vaccine vector expressing Streptococcus pneumoniae PspA)

Snippet

Sponsor: Arizona State University | Conditions: Pneumonia | Phase 1 | Status: COMPLETED